Matthew Cohen, MD
Internal Medicine · Chester, PANPI 1437219748
Payments from drug & device makers
Across 236 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$790
- Novo Nordisk$719
- AstraZeneca$386
- Lilly USA, LLC$317
- Novartis$223
- Pfizer$175
- plus $1K from 22 others
What the payments were for
- Consulting fees$150%
- Food & beverage$3,92999%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $790 |
| Novo Nordisk | 48 | $719 |
| AstraZeneca | 22 | $386 |
| Lilly USA, LLC | 19 | $317 |
| Novartis | 12 | $223 |
| Pfizer | 11 | $175 |
| GSK | 9 | $164 |
| Boehringer Ingelheim | 7 | $152 |
| Intercept Pharmaceuticals, Inc. | 9 | $146 |
| Amarin Pharma, Inc. | 12 | $135 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $112 |
| Johnson & Johnson | 5 | $94 |
| Exact Sciences | 3 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $73 |
| Astellas Pharma US Inc | 4 | $71 |
| Sanofi-aventis U.S. LLC | 4 | $70 |
| Merck | 3 | $44 |
| Bayer | 3 | $43 |
| Amgen | 2 | $30 |
| Abbott | 2 | $26 |
| Eisai Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Concordia Pharmaceuticals Inc. | 1 | $12 |
| Dynavax Technologies Corporation | 1 | $7 |
How this compares
$3,974 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 216 | $221,140 |
| OzempicSemaglutide | 148 | $155,604 |
| JardianceEmpagliflozin | 151 | $134,327 |
| EliquisApixaban | 134 | $100,240 |
| FarxigaDapagliflozin Propanediol | 96 | $71,256 |
| XifaxanRifaximin | 21 | $67,051 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $52,078 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $46,432 |
| LinzessLinaclotide | 83 | $43,699 |
| XareltoRivaroxaban | 38 | $42,070 |
| JanuviaSitagliptin Phosphate | 49 | $41,426 |
| MounjaroTirzepatide | 34 | $34,428 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 68 | $26,067 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $17,460 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $14,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $317 | $255,568250 claims |
| Novo NordiskOzempic | $719 | $155,604148 claims |
| Boehringer IngelheimJardiance | $152 | $134,327151 claims |
| PfizerEliquis, Nurtec Odt | $175 | $111,838146 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $386 | $89,487132 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $112 | $67,05121 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $164 | $63,89193 claims |
| AbbVieLinzess | $790 | $43,69983 claims |
| Johnson & JohnsonXarelto | $94 | $42,07038 claims |
| MerckJanuvia | $44 | $41,42649 claims |
| Astellas Pharma US IncMyrbetriq | $71 | $10,47821 claims |
| NovartisEntresto | $223 | $8,73813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Chester
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.